Cancel
Robert A. Copeland
Founder, President, Chief Scientific Officer
@
Accent Therapeutics
w2.zyki67wh@ysykvu18.6wv
Sign up to see email
Known information
- Holds a PhD
- Provided a major symposium presentation on inhibition of key RNA-modifying enzymes as precision cancer therapeutics at the AACR 2024 Annual Meeting
- Has a background in RNA-modifying enzyme inhibitors as precision cancer therapeutics
- Presented data on DHX9 and KIF18A inhibitor activity in multiple tumor types
- Has expertise in developing small molecule precision cancer therapies
- Has contributed to the validation of DHX9 as a new target in breast cancer and other solid tumors with loss-of-function mutations in the DNA damage repair genes BRCA1 or BRCA2
- Has been involved in preclinical investigations expanding the potential of lead programs in cancer therapy
About Accent Therapeutics
Accent Therapeutics, based in Lexington, MA, develops small molecule therapeutics targeting RNA-modifying proteins for cancer treatment. The company has a partnership with AstraZeneca and has raised $75 million in Series C financing.
Report inaccurate information
